Get ready for the Precision Medicine World Conference

The Precision Medicine World Conference will be held September 24-25 at the Washington Duke Inn. Get to know some of the speakers and topics ahead of time:

Why We Need Public-Private Partnership (PPP) to Foster Drug Discovery

Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden. Late stage drug development is the most costly area of drug R&D and it also has the highest attrition rate with huge financial implications for sponsors. Increasing the probability of success and the number of new chemical entities in pharmaceutical pipelines requires optimization of drug discovery and clinical translational efforts, along with a decrease of late-stage drug failures.

Call by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine

“I suggest that a broad based blue ribbon taskforce be created to quantify the needs for a growing precision medicine workforce. Based on the taskforce’s recommendations, the changes needed in educational curricula as well as new training pathways could be determined. A comprehensive needs assessment for the workforce underlying the advancement of precision medicine is a vital, given the rapid expansion of the field and its potential to improve health care delivery.”

Interview with David Hong from Karius

Dr. Hong joined Karius after 14 years at Stanford University, where he was Clinical Assistant Professor of Pediatric Infectious Diseases. He also served as chief of pediatric infectious diseases at the Stanford-affiliated Santa Clara Valley Medical Center. His prior studies in respiratory virus infections in children focused on host–pathogen interactions and novel adjuvants for respiratory virus vaccines

Interview with Ralph Snyderman from Duke University

Ralph Snyderman, MD is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine at Duke University from 1989 to July 2004 and led the transition of this excellent medical center into an internationally recognized leader of academic medicine.

Interview with Gunnar Carlsson from Ayasdi

Gunnar Carlsson is one of the most renowned mathematicians in the world. He is Ayasdi’s President and a co-founder and has an undergraduate degree from Harvard University and a doctorate from Stanford, where he was Chair of the Department of Mathematics from 1995 -1998.Over the past 35 years, Gunnar has taught at the University of Chicago, University of California, Princeton University, and since 1991, Gunnar has been a professor of mathematics at Stanford University, where he has been a thought leader in a branch of mathematics called topology, the study of shape.

Interview with Patrick Conway from Blue Cross Blue Shield of North Carolina

Patrick Conway, MD, MSc, joined Blue Cross and Blue Shield of North Carolina as president and CEO-elect on Oct. 1, 2017. He will succeed Brad Wilson as CEO at Wilson’s retirement by the end of 2017. Conway most recently served as Deputy Administrator for Innovation and Quality at the federal Centers for Medicare and Medicaid Services (CMS). In this role he also held the position of Director of the Center for Medicare and Medicaid Innovation (CMMI). As the most senior non-political leader at CMS, he worked in both Republican and Democratic administrations and is considered one of the driving forces behind the national movement to value-based care, with health care payments tied to quality and innovation.

Interview with Honoree Mary Relling, PMWC Duke 2018 Luminary Honoree

Mary has been a pioneer in both the science and clinical application of pharmacogenomics. Her research has resulted in seminal laboratory discoveries that unraveled the mechanisms of leukemogenesis and drug resistance; the indentification of novel therapeutic targets, and the integration of biologic, genomic, and pharmacologic discoveries into comprehensive clinical protocols, leading to a markedly improved cure rate for children with acute lymphoblastic leukemia.

Interview with Cathleen Colon-Emeric from Duke University School of Medicine

Dr. Cathleen Colón-Emeric, MD, MHS is Professor of Medicine and Associate Dean for Research Mentoring at Duke University, a Senior Fellow for the Duke Center for Aging and Human Development, and the Associate Director of the Geriatric Research Education and Clinical Center at the Durham VA Medical Center. Dr. Colón-Emeric is a clinical researcher, focusing on fracture prevention in older adults, particularly after hip fracture and in the long-term care setting.

All of Us Research Program Aims to Create Diverse Research Data Resource

In the age of big DNA data, it is important to remember that accumulating large amounts of data is not enough. Equally important is keeping the DNA data that participants provide as diverse as possible to allow us to generate answers to questions about how different variables impact people differently.